Use of Long Read Genome Sequencing in Patients Suffering From Neurodevelopmental Troubles

Neurologic Disorder Clinical Trial

— HiFi-NDD  

Official title:

Use of Long Read Genome Sequencing in Patients Suffering From Neurodevelopmental Troubles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05643274
• Other study ID #: RC22_0373
• Status: Completed
• Start date: December 19, 2022
• Est. completion date: March 8, 2024

Study information

• Verified date: April 2024
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients with neurodevelopmental diseases and their families need to identify the genetic cause of the disease to allow for recognition of the disability, genetic counseling, and possible hope for participation in therapeutic research studies. Access to high-throughput genomic exome or genome analysis allows the identification of a genetic cause for approximately half of the patients. However, families with no result or with a variant of unknown significance after these tests may find themselves in a new diagnostic impasse. The high-throughput sequencing used today generates sequences of the order of 100 base pairs (so-called "short read" sequencing). This allows an analysis of about 90% of the genome. However, many regions are not accessible in regions of interest for the genetic diagnosis of rare diseases. Long fragment sequencing generates sequences that are about 20 times larger and its use has recently made it possible to sequence the human genome almost completely (https://www.science.org/doi/10.1126/science.abj6987). The main contribution lies in the analysis of complex regions of the genome such as segmental duplications or centromeric regions. It is likely that this technology increases the sensitivity of detection of genetic variants in patients with genetic diseases. Its contribution should be studied in patients for whom no genetic cause has been identified by classical techniques. This study aim to investigate the contribution of long fragment genome sequencing.

Description:

Ten families with a child suffering from a neurodevelopmental disease will be recruited by geneticists being part of the CLAD-Ouest. An EDTA blood sample will be taken from the patient and their parents (trio analysis). The blood samples will then be used to extract nucleic acids (DNA). The blood samples will be sent and centralized to the genetics laboratory of the Nantes University Hospital. The DNA will be extracted and anonymized. The files generated after DNA sequencing will have as an identification key the anonymization number provided at the time of inclusion of the individual in the study. The raw data and VCF files will be uploaded to the BIRD computing cluster in Nantes, where they will be stored for the duration of the study (2 years). The different university hospitals will then be able to retrieve the data and analyze the variants identified in the patients recruited by their center. A centralized analysis to annotate, filter and interpret the variants will be performed by a group of bioinformaticians and biologists from HUGO (University Hospital from the Grand Ouest). Long-term archiving of the data will be performed at the Nantes University Hospital.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 8, 2024
• Est. primary completion date: March 8, 2023
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria for patients:

• Patient (child or adult) presenting neurodevelopmental troubles strongly suspected to suffer from a rare genetic disease (familial or very severe).
• Negative outcome for short read sequencing of the trio (child and parents).
• Informed consent to the study by the patient (if applicable) or their legal representatives if under-aged or under guardianship.
• Patients benefiting from the social security (French health care system).

Inclusion criteria for Parents :

• Possible recruitment of both parents matching the inclusion criteria.
• Informed consent form signed for their own participation.
• Parents benefiting from the social security (French health care system).

Exclusion Criteria for patients:

• Genetic predisposition already identified explaining the disease.
• Paients for which the WGS for the trio has not been performed.
• Patients having withdrawn their consent.

Exclusion Criteria fo Parents :

• Pregnant or lactating woman.
• Parents under guardianship or curatorship.
• Parents also presenting a neurodevelopmental deficiency.

Related Conditions & MeSH terms

• Developmental Delay Disorder
• Developmental Disabilities
• Genetic Disease
• Genetic Diseases, Inborn
• Growth Disorders
• Nervous System Diseases
• Neurologic Disorder

Locations

Country	Name	City	State
France	Angers University Hospital	Angers	Maine-et-Loire
France	Brest University Hospital	Brest	Finistère
France	Nantes University Hospital	Nantes	Loire-Atlantique
France	Rennes University Hospital	Rennes	Ille-et-Vilaine
France	Tours University Hospital	Tours	Indre-et-Loire

Sponsors (5)

Lead Sponsor	Collaborator
Nantes University Hospital	Rennes University Hospital, University Hospital, Angers, University Hospital, Brest, University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Use of long read sequencing in patients suffering from a neurodevelopmental disease without pathogenic or probably pathogenic variation identified by short read sequencing	Identification of a genetic diagnosis : detection of one or several variant(s) - nucleotidic, change in copy number, structural variants- of class 4 or 5 (probably pathogenic or pathogenic), explaining the genetic origin of the neurodevelopmental pathology	through study completion, an average of 2 years
Secondary	Analysis of the implementation of the long read sequencing of trios (patients and parents)	Measurement of the failing rate of long read sequencing, turn around time between sequencing and results available to clinical team	through study completion, an average of 2 years